Aurora Cannabis (ACB) said it has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealand based MedLeaf Therapeutics. The company said, “The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Morning Movers: Circle rises following regulatory framework for stablecoins
- Aurora Cannabis Achieves Record Revenue and EBITDA in Fiscal 2025
- Aurora Cannabis expects strong global cannabis revenue in Q1
- Aurora Cannabis reports Q4 revenue C$90.5M vs. C$67.4M last year
- Options Volatility and Implied Earnings Moves Today, June 18, 2025